West Virginia 2026 Regular Session

West Virginia Senate Bill SB1055

Introduced
2/21/26  
Refer
2/21/26  
Report Pass
2/24/26  

Caption

Conducting rate study for substance use disorder

Impact

If enacted, SB1055 would significantly impact state laws concerning the reimbursement of mental health services, particularly those addressing substance use disorders. By ensuring that Medicaid reimbursement rates are evaluated and adjusted periodically based on reliable data, the bill seeks to improve service delivery and access for individuals needing substance use treatment. Furthermore, these changes could also lead to better financial management of state resources allocated for these services, supporting the long-term sustainability of substance use programs.

Summary

Senate Bill 1055 aims to amend the Code of West Virginia by establishing a structured framework for conducting rate studies related to substance use disorder services. The bill mandates the Bureau for Medical Services to implement a data-informed methodology for reviewing Medicaid reimbursement rates, with the intent to enhance transparency and ensure that these rates accurately reflect the costs and utilization of these critical services. The legislative findings articulate the need for regular reviews to maintain program integrity while supporting access to necessary treatment options.

Sentiment

The sentiment surrounding SB1055 appears to be generally positive among stakeholders who advocate for greater accountability and efficiency in Medicaid spending. Proponents emphasize the importance of evidence-based approaches in determining pricing structures for substance use disorder services, highlighting the potential for improved care quality and accessibility. There may, however, be some apprehension among providers about how the rate reviews could affect their funding and service delivery models.

Contention

While SB1055 is largely welcomed for its focus on transparency and accountability, potential points of contention may arise regarding the specifics of the methodologies used in the rate studies. Stakeholder engagement is a crucial aspect of the bill, and how well the Bureau incorporates feedback from service providers and consumers may influence its acceptance and effectiveness. Some stakeholders might express concerns regarding the adequacy of data collection and analysis, fearing that insufficient consideration of regional variations in service delivery could lead to inequitable reimbursement rates.

Companion Bills

No companion bills found.

Previously Filed As

WV SB515

Relating to involuntary hospitalization for substance use disorder

WV HB3306

Involuntary treatment for substance use disorder (Cassie’s Law)

WV HB2861

Mental Health and Substance Use Disorders Insurance Coverage Protection Act

WV SB723

Relating to clinical inpatient medical treatment centers for substance use disorder

WV SB939

Relating to testing for substance use disorder

WV SCR14

Requesting Joint Committee on Government and Finance study substance use disorder in WV

WV HB3070

Relating to the requirement of insurance coverage for a nonopioid drug for a person diagnosed with a substance use disorder

WV SB867

Prohibiting payment to residential substance use disorder treatment facilities that do not meet certain requirements

WV SB761

Creating Joel Archer Substance Abuse Intervention Act

WV HB2347

The Joel Archer Substance Abuse Intervention Act.

Similar Bills

No similar bills found.